Ipsen (IPSEY) & Its Competitors Critical Survey

Ipsen (OTCMKTS: IPSEY) is one of 25 publicly-traded companies in the “Diagnostic substances” industry, but how does it weigh in compared to its competitors? We will compare Ipsen to related companies based on the strength of its earnings, risk, institutional ownership, profitability, valuation, analyst recommendations and dividends.

Risk & Volatility

How to Become a New Pot Stock Millionaire

Ipsen has a beta of -0.04, suggesting that its stock price is 104% less volatile than the S&P 500. Comparatively, Ipsen’s competitors have a beta of 1.44, suggesting that their average stock price is 44% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Ipsen and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ipsen 0 0 1 0 3.00
Ipsen Competitors 102 373 571 19 2.48

As a group, “Diagnostic substances” companies have a potential upside of 7.19%. Given Ipsen’s competitors higher probable upside, analysts plainly believe Ipsen has less favorable growth aspects than its competitors.

Dividends

Ipsen pays an annual dividend of $0.17 per share and has a dividend yield of 0.4%. Ipsen pays out 18.3% of its earnings in the form of a dividend. As a group, “Diagnostic substances” companies pay a dividend yield of 1.2% and pay out 41.9% of their earnings in the form of a dividend.

Profitability

This table compares Ipsen and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Ipsen N/A N/A N/A
Ipsen Competitors -885.83% -65.54% -25.27%

Institutional and Insider Ownership

0.0% of Ipsen shares are owned by institutional investors. Comparatively, 52.8% of shares of all “Diagnostic substances” companies are owned by institutional investors. 13.2% of shares of all “Diagnostic substances” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Ipsen and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Ipsen $2.27 billion $307.78 million 42.27
Ipsen Competitors $308.35 million $13.85 million -44.68

Ipsen has higher revenue and earnings than its competitors. Ipsen is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Summary

Ipsen beats its competitors on 9 of the 15 factors compared.

Ipsen Company Profile

Ipsen S.A. operates as a pharmaceutical company worldwide. It operates in two segments, Primary Care and Specialty Care. The company offers drugs in oncology, endocrinology, neurology, gastroenterology, cognitive disorders, and rheumatology areas. Its products include Somatuline, which is an injectable treatment for acromegaly and neuroendocrine tumors; Decapeptyl, a synthetic hormone made of triptorelin and decapeptide analog of gonadotrophin releasing hormone, for the treatment of advanced metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, and female sterility; and Hexvix, a photosensitizing agent, for detection and resection of non invasive bladder cancer. The company also provides Cabometyx, a tablet formulation of cabozantinib for renal cell carcinoma; Cometriq for medullary thyroid cancer; Dysport for motor disorders and muscular spasticity; NutropinAq, a liquid formulation, for treating growth failure in children due to growth hormone deficiency in adults; and Increlex used for long-term treatment of growth failure in children and adolescents. In addition, it offers Smecta, a formulation for use in the treatment of chronic and acute diarrhea; Forlax, an osmotic laxative indicated for the symptomatic treatment of constipation in adults and children; and Tanaka for mild cognitive impairment related to age, pathophysiological deficiencies, vertigo, retinal deficits, acute or chronic hearing impairment, and tinnitus. Further, the company provides Adenuric for the treatment of gout; and Adrovance for treating post-menopausal osteoporosis. Additionally, it is developing chimeric somastatin and dopamine agonist molecule, VSN16R, OPS201, and OPS202 drugs, as well as botulinum toxin. Ipsen S.A. has a strategic agreement with Arix Bioscience plc to develop and commercialize various therapies. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy S.A.

Receive News & Ratings for Ipsen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ipsen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply